Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Takeda's patients

    How Takeda is integrating the patient perspective into drug development

    Takeda is not waiting for FDA to clarify the next steps in patient-centered drug development, and is already using patient input to design clinical trial protocols in leukemia.

    Published on 1/26/2015
  • Box: FDA commitment

    Takeda's patients FDA commitment Guidance from FDA on patient-focused drug development could help Takeda Pharmaceutical Co. Ltd. enhance its current efforts as well as identify new opportunities to engage and …

    Published on 1/26/2015
  • Box: Payers in step?

    Takeda's patients Payers in step? Pharmacy benefits managers and regional payers have told BioCentury they are interested in engaging with patients to ensure the drugs that are being paid for are valuable to …

    Published on 1/26/2015
  • Partitioning HCV

    Handicapping the HCV price war; Medicaid wild card

    Gilead has responded swiftly to AbbVie's first shot in the HCV price war, but the victor could depend on how Medicaid plans respond.

    Published on 1/19/2015
  • Box: Room for appeal?

    Partitioning HCV Room for appeal? All the exclusive formulary deals for HCV drugs allow patients to access excluded products if the preferred drug is contraindicated. Physicians who spoke to BioCentury had …

    Published on 1/19/2015
  • Figure: Coming out ahead, maybe

    Partitioning HCV Coming out ahead, maybe A back-of-the-envelope analysis of plausible rebate scenarios under the exclusive HCV deal between AbbVie Inc. (NASDAQ:ABBV) and Express Scripts Holding Co. (NASDAQ:ESRX) …

    Published on 1/19/2015
  • Figure: HCV landgrab

    Partitioning HCV The battle between Gilead Sciences Inc. (NASDAQ:GILD) and AbbVie Inc. (NASDAQ:ABBV) to secure HCV lives for their new drugs has been mostly focused on patients with genotype 1 infection who are …

    Published on 1/19/2015
  • Buyside view XXIII: Milestones galore

    2015 sees investors focus on big launches, cancer combos, NASH and gene therapy

    In 2015 investors are focused on big product launches, and data for cancer immunotherapy combos, NASH and gene therapy.

    Published on 1/12/2015
  • Table: 2015 milestones

    Milestones galore 2015 milestones Selected products with Phase III or regulatory milestones expected in 2015. Products up for approval this year are listed in "Approval Watch," see page 12. (A) Being acquired by …

    Published on 1/12/2015
  • Table: Approval watch

    Milestones galore Approval watch Selected products up for approval in 2015. (A) Being acquired by Merck & Co. Inc. (NYSE:MRK); Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event …

    Published on 1/12/2015
  • Table: New products to watch

    Milestones galore New products to watch Selected drugs that received regulatory approval in 2014. (A) Prior approvals in parentheses; (B) Being acquired by Merck & Co. Inc. (NYSE:MRK); Source: BCIQ: BioCentury …

    Published on 1/12/2015
  • Table: Post-launch report

    Milestones galore Post-launch report Three products that were first approved in 2013 have already recorded 2014 sales over $1 billion each. Two of them are oral HCV drugs — Sovaldi sofosbuvir from Gilead Sciences …

    Published on 1/12/2015
  • Table: Top biotech products

    Milestones galore Top biotech products At least 28 drugs developed and marketed by biotechs are expected to have more than $1 billion in 2014 sales. Antivirals from Gilead Sciences Inc. (NASDAQ:GILD) account for …

    Published on 1/12/2015
  • Figure: London vs. Europe

    Grow early, grow often London vs. Europe Both the BioCentury Europe and the BioCentury London indexes ended the year up more than 16%. The BC Europe posted a 24% gain, with advancers beating decliners 12-7. The …

    Published on 1/5/2015
  • Figure: Results by market cap

    Grow early, grow often Results by market cap The top market cap tier — companies valued above $5 billion — outperformed all other market cap segments in 2014, gaining 32% on the year. Of the 31 companies in the …

    Published on 1/5/2015
  • Table: 4Q approvals and setbacks

    Grow early, grow often 4Q approvals Selected fourth quarter approvals. (A) Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is being acquired by Merck & Co. Inc. (NYSE:MRK) Company Approval AbbVie Inc. (NYSE:ABBV)/…

    Published on 1/5/2015
  • Table: Index performance

    Grow early, grow often Index performance The BioCentury 100, NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices all ended the year well ahead of the general market benchmarks. The BC100 lagged …

    Published on 1/5/2015
  • Table: Restructuring watch

    Grow early, grow often Restructuring watch At least two companies reported workforce reductions in the fourth quarter compared to at least 13 in the same period last year. Tied with 1Q14, this is the smallest …

    Published on 1/5/2015
  • 2015 Financial Markets Preview: Show me in 2015

    How buysiders expect maturing sector to deliver growth in 2015

    Buysiders expect 2015 to be driven by mature large caps while follow-ons will be open for small caps that deliver on expectations.

    Published on 1/5/2015
  • Figure: Healthcare/biotech fund flows

    Show me in 2015 Healthcare/biotech fund flows More than $6 billion flowed into healthcare/biotech funds last quarter, bringing net fund flows to $18 billion for the year. The S&P 500 Health Care Index gained 7% …

    Published on 1/5/2015
  • Figure: M&A activity

    Show me in 2015 M&A activity The aggregate transaction value for M&A deals completed in 2014 reached a record $86 billion, beating the previous high of $80 billion in deals in 2011 and more than 2.6x the $32.5 …

    Published on 1/5/2015
  • Figure: Price-to-earnings: BT vs RX

    Grow early, grow often Price-to-earnings: BT vs RX The average biotech P/E ended the year at 22.4, about 1.3x the 17.7 average for big pharma. A year ago, biotech's P/E was 1.6x big pharma's multiple. The 13% …

    Published on 1/5/2015
  • Figure: Raised by market cap

    Show me in 2015 Raised by market cap In 2014, 467 public companies raised $45.5 billion vs. 401 companies that raised $31.2 billion in 2013. The increase was bolstered by large debt financings from a handful of …

    Published on 1/5/2015
  • Table: Follow-on performance

    Show me in 2015 Follow-on performance In 2014, $11 billion was raised via 150 follow-on offerings, above the $10 billion raised from 139 deals in 2013. The 2014 class is up a median of 14% from their postmoney …

    Published on 1/5/2015
  • Table: IPO performance

    Show me in 2015 IPO performance Twenty-three companies raised $2.1 billion in IPOs in 4Q14, bringing the total for 2014 to 112 companies that raised $9 billion. In 2013, 60 IPOs raised $3.9 billion. The median …

    Published on 1/5/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993